Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 75, Issue 2, 2012, Pages 63-75

  Friedrich, Karen ^a   Vieira, Flávia A ^a,b   Porrozzi, Renato ^a   Marchevsky, Renato S ^a   Miekeley, Norbert ^b   Grimaldi, Gabriel ^a   Paumgartten, Francisco J R ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; MEGLUMINE ANTIMONATE; ANTIPROTOZOAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

ADRENAL GLAND; ANIMAL EXPERIMENT; ARTICLE; BONE; BRAIN REGION; COLON; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERYTHROCYTE LEVEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; GALLBLADDER; HEART; ION PAIR CHROMATOGRAPHY; KIDNEY; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; LIVER; LOW DRUG DOSE; LYMPH NODE; MACACA MULATTA; MASS SPECTROMETRY; MOUSE; NAIL; NONHUMAN; ONLINE MONITORING; PANCREAS; PRIORITY JOURNAL; SKELETAL MUSCLE; SKIN; SPLEEN; STOMACH; THYMUS; THYROID GLAND; TOOTH; TOXICITY TESTING; ANIMAL; ATOMIC ABSORPTION SPECTROMETRY; BLOOD; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE; HALF LIFE TIME; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METABOLISM; OXIDATION REDUCTION REACTION; REPRODUCIBILITY; SKIN LEISHMANIASIS; TISSUE DISTRIBUTION;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; FEMALE; HALF-LIFE; INJECTIONS, INTRAMUSCULAR; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MACACA MULATTA; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; OXIDATION-REDUCTION; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ATOMIC; THYROID GLAND; TISSUE DISTRIBUTION;

EID: 84856151090     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2012.624826     Document Type: Article

References (22)

1. Abdallah, A., and, Saif, M. 1962. Trace studies with antimony 124 in man. In Bilharziasis, Edited by: Wolstenholme, G. E. W., O'Connor, M., Wolstenholme, G. E. W. and O'Connor, M. 287-309. London: Churchill. (Ciba Foundation Symposium)
2. Andrade, M. C. R., Penedo, M. C. T., Ward, T., Silva, V. F., Bertolini, L. R., Roberts, J. A., Leite, J. P. G., and, Cabello, P. H. 2004. Determination of genetic status in a closed colony of rhesus monkeys (Macaca mulatta). Primates, 45: 183-86. (Pubitemid 39447750)
3. Baiocco, P., Colotti, G., Franceschini, S., and, Ilari, A. 2009. Molecular basis of antimony treatment in leishmaniasis. J. Med. Chem, 52: 2603-12.
4. Brady, F. J., Lawton, A. H., Cowie, D. B., Andrews, H. L., Ness, A. T., and, Ogden, G. F. 1945. Localization of trivalent antimony following intravenous administration to dogs infected with Dirofilaria immitis. Am. J. Trop. Med. Hyg., 25: 103-7.
5. Chulay, J. D., Fleckenstein, L., and, Smith, D. H. 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg, 82: 69-72. (Pubitemid 18056241)
6. Croft, S. L., and, Coombs, G. H. 2003. LeishmaniasisCurrent chemotherapy and research advances in the search for novel drugs. Trends Parasitol, 19: 502-8. (Pubitemid 37329659)
7. Cruz, A., Rainey, P. M., Herwaldt, B. L., Stagni, G., Palacios, R., Trujillo, R., and, Saravia, N. G. 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J. Infect. Dis, 195: 602-8. (Pubitemid 46214405)
8. David, C., and, Craft, N. 2009. Cutaneous and mucocutaneous leishmaniasis. Dermatol. Ther, 22: 491-502.
9. Dorea, J. G., Costa, J. M., Holzbecher, J., Ryan, D. E., and, Marsden, P. D. 1987. Antimony accumulation in hair during treatment of leishmaniasis. Clin. Chem, 33: 2081-82.
10. Felicetti, S. A., Thomas, R. G., and, McClellan, R. O. 1974. Metabolism of two valence states of inhaled antimony in hamsters. Am. Ind. Hyg. Assoc. J, 35: 292-300.
11. Grimaldi, G. Jr., Porrozzi, R., Friedrich, K., Teva, A., Marchevsky, R. S., Vieira, F., Miekeley, N., and, Paumgartten, F. J. 2010. Comparative efficacies of two antimony regimens to treat Leishmania braziliensis -induced cutaneous Leishmaniasis in rhesus macaques (Macaca mulatta). Antimicrob. Agents Chemother, 54: 502-5.
12. Lynch, B. S., Capen, C. C., Nestmann, E. R., Veenstra, G., and, Deyo, J. A. 1999. Review of subchronic/chronic toxicity of antimony potassium tartrate. Regul. Toxicol. Pharmacol, 30: 9-17. (Pubitemid 29439923)
13. Miekeley, N., Mortari, S. R., and, Schubach, A. O. 2002. Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis. Anal. Bioanal. Chem, 372: 495-502. (Pubitemid 40819290)
14. Miranda, E. S., Miekeley, N., De-Carvalho, R. R., and, Paumgartten, F. J. R. 2006. Developmental toxicity of meglumine antimoniate and transplacental transfer of antimony in the rat. Reprod. Toxicol, 21: 292-300. (Pubitemid 43294559)
15. Nieto, J., Alvar, J., Mullen, A. B., Carter, K. C., Rodrguez, C., San Andrés, M. I., San Andrés, M. D., Baillie, A. J., and, González, F. 2003. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob. Agents Chemother, 47: 2781-87. (Pubitemid 37040248)
16. Pamplin, C. L., Desjardins, R., Chulay, J., Tramont, E., Hendricks, L., and, Canfield, C. 1981. Pharmacokinetics of antimony during sodium stibogluconate therapy for cutaneous leishmaniasis. Clin. Pharmacol. Ther, 29: 270-71. (Pubitemid 11132933)
17. Poon, R., Chu, I., Lecavalier, P., Valli, V. E., Foster, W., Gupta, S., and, Thomas, B. 1998. Effects of antimony on rats following 90-day exposure via drinking water. Food Chem. Toxicol, 36: 21-35. (Pubitemid 28059890)
18. Porrozzi, R., Pereira, M. S., Teva, A., Volpini, A. C., Pinto, M. A., Marchevsky, R. S., Barbosa, A. A. Jr., and, Grimaldi, G. Jr. 2006. Leishmania infantum -induced primary and challenge infections in rhesus monkeys (Macaca mulatta): A primate model for visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 100: 926-37. (Pubitemid 44145303)
19. Rees, P. H., Keating, M. I., Kager, P. A., and, Hockmeyer, W. T. 1980. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet, 2: 226-29. (Pubitemid 10084826)
20. Teva, A., Porrozzi, R., Oliveira-Neto, M. P., and, Grimaldi, G. J. 2005. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N -methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model. J. Parasitol, 91: 976-78. (Pubitemid 41324793)
21. Valladares, J. E., Alberola, J., Esteban, M., and, Arboix, M. 1996. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs. Vet. Rec, 138: 181-83. (Pubitemid 26063058)
22. Zaghloul, I. Y., Radwan, M. A., Al Jaser, M. H., and, Al Issa, R. 2010. Clinical efficacy and pharmacokinetics of antimony in cutaneous leishmaniasis patients treated with sodium stibogluconate. J. Clin. Pharmacol, 50: 1230-37.